Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders .
Our mission is to radically improve the health of patients suffering from incurable life threatening conditions. We do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.
The safety of our MPS IIIA trial participants is our top priority. At Lysogene we are actively and continuously working with our clinical trial sites, regulatory authorities and ethics committees to assess potential impacts and reduce families’ potential exposure to COVID-19, whilst continuing to provide medically necessary study care. If you have any concern or question, please contact your study doctor.